GE has completed the acquisition of Thermo Fisher’s HyClone cell culture media and sera, and gene modulation and magnetic beads businesses. The acquisition expands GE’s technologies and services for the discovery and manufacture of new medicines, vaccines and diagnostics in its Life Sciences business.   Kieran Murphy, president and chief executive officer of GE Healthcare’s Life Sciences business, said, “GE Healthcare has built a world-class set of technologies for the life sciences sector, and ...